Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 29788331.
- Also identified by DOI 10.1093/cid/ciy416 and PMC identifier 6233673.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.
Medical subject headings
- Antitubercular Agents
- Heart
- Levofloxacin
- Tuberculosis, Multidrug-Resistant